Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

More documents

Recommendations

Info

Tab. 9.1 Reports on the use of DC for cancer immunotherapy 9.8 Phase I/II Clinical Trials Type of cancer Antigen Center DC type Route of Number of Response reported Reference immuni- individuals zation immunized NHL idiotype Standford Im Mo i.v. > s.c. 4 1 CR, 1 PR; antigen-specific lymphocyte proliferation Multiple myeloma Multiple myeloma Multiple myeloma (follow-up) Multiple myeloma Chronic myeloid leukemia idiotype protein idiotype protein + KLH idiotype protein + KLH idiotype protein + KLH leukemic DC (Ph1 + ) Melanoma Mart-1, gp100 peptides Melanoma Melan-A, gp100 Melanoma Melan-A, tyrosinase, MAGE3 + influenza MP Melanoma lysate/peptide mix + KLH Melanoma MAGE A1/ A3 peptide Melanoma tyrosinase, gp100 peptides Melanoma Melan-A or MAGE-1 tyrosinase 189 Cardiff Im Mo i.v. 1 antigen-specific lymphocyte proliferation response, antibodies 137 Stanford blood i.v. 12 11/12 KLH, 2/12 idiotype-specific lymphocyte proliferation (CR) 139 Stanford blood i.v. 26 24/26 KLH, 4/26 idiotype-specific lymphocyte proliferation (CR) 140 Cardiff Im Mo i.v. 6 Increase CTL proliferation in 3/6; antibodies; idiotype proliferation; IFN-g ELISA 174 Ninomaru Ma Mo i.v. 1 Ph1-specific CTL 161 Bethesda Im Mo i.v. 10 increased CTL 1/5, 1 PR; metastasis regression 76 Freiburg CD34 + i.v. 14 peptide DTH, met regression, vitiligo 89 Dallas CD34 + i.d. 18 antigen-specific ELISPOT 16/18; met regression; delayed progression 91 Zçrich Im Mo i.n. 16 DTH to peptide and KLH, 2 CR, 3 PR, met regression Brussels Im Mo i.v. > s.c. 24 increase in peptidespecific CTL 14/24 Los Angeles Im Mo i.v. 16 1 CR, 2 SD, 5/16 IFN-g ELISA response Mainz Im Mo versus Ma Mo i.n. 11 3 PR, 2 SD of 8 evaluable 5/7 CTL Ma Mo; 1/7 CTL Im Mo 106 132 142 143 144
190 9 Dendritic Cells and Cancer: Prospects for Cancer Vaccination Tab. 9.1 (continued) Type of cancer Antigen Center DC type Route of Number of Response reported Reference immuni- individuals zation immunized Melanoma MAGE-3A1, HLA-A1 peptide Melanoma MAGE-3A1, HLA-A2 peptide Erlangen Ma Mo s.c., i.d. > i.v. Erlangen Ma Mo s.c., i.d. > i.v. 11 Peptide-specific CTL 6/11, metastasis regression 6/11 8 peptide-specific CTL 8/8 Melanoma tumor/allo Berlin Activated s.c. 16 1 CR, 1 PR, 5 SD 178 peripheral peripheral blood blood mononuclear mononuclear cell hybrid cells Breast/ovarian Her2/neu, MUC-1 peptides Tçbingen Ma Mo s.c. 10 5/10 CTL 159 Breast tumor lysate Osaka Mo i.n. 1 metastasis regression 160 Prostate fusion protein GM- CSF + PAP Prostate PSMA P1 and P2 peptides Prostate PMSA P1 and P2 peptides Prostate (follow-up) PMSA P1 and P2 peptides Prostate fusion protein GM- CSF + PAP Renal cell carcinoma Renal cell carcinoma tumor/allo DC hybrid cell lysate + KLH Seattle blood i.v. 31 lymphocyte proliferation to GM-CSF Seattle Im Mo i.v. 51 and PAP 7 PR, peptidespecific CTL Seattle Im Mo i.v. 37 1 CR, 10 PR 149 Seattle Im Mo i.v. 37 DTH and cytokine production relates to clinical response Rochester blood i.v. 13 Peptide-specific lymphocyte proliferation to T antibody PAP in 20/31 (delayed disease pro- Gættingen Ma Mo i.v. 17 gression) 4 CR, metastasis regression, 1 mass reduction >0% 117 Innsbruck Ma Mo i.v. 4 1 PR; KLH IFN-g responses 145 176 177 72 148 151 157
Page 1 and 2:
Cancer Immune Therapie: Current and
Page 3 and 4:
Editors: Dr. Gernot Stuhler Univers
Page 5 and 6:
VI Preface Recent years have seen a
Page 7 and 8:
VIII Contents 2.5.3 Antigens Encode
Page 9 and 10:
X Contents 6.4.2 Natural Killer (NK
Page 11 and 12:
XII Contents 9.6 Loading DC with An
Page 13 and 14:
XIV Contents 14.2.2.1 Cancer-specif
Page 15 and 16:
List of Contributors Richard Bucala
Page 17 and 18:
Color Plates Fig. 5.2 The MHC class
Page 19 and 20:
Fig. 5.5 Different immune effector
Page 21 and 22:
Fig. 5.17 Possible pathway for the
Page 23 and 24:
Fig. 6.2 T lymphocytes in the tumor
Page 25 and 26:
Index a acidic and basic fibroblast
Page 27 and 28:
±, see also tumors cationic lipids
Page 29 and 30:
e EBV see Epstein-Barr virus EDR se
Page 31 and 32:
immature Mo-DCs 184 immune cells ±
Page 33 and 34:
MHC class I antigen-processing mach
Page 35 and 36:
±, onco- 209 ±, over-expressed ce
Page 37 and 38:
TICD see tumor-induced cell death T
Page 39 and 40:
Part 1 Tumor Antigenicity Cancer Im
Page 41 and 42:
4 1 Search for Universal Tumor-Asso
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
10 1 Search for Universal Tumor-Ass
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
18 2 Serological Determinants On Tu
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
30 Cancer Immune Therapie: Current
Page 69 and 70:
32 3 Processing and Presentation of
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
42 4 T Cells In Tumor Immunity cult
Page 81 and 82:
44 4 T Cells In Tumor Immunity cell
Page 83 and 84:
46 4 T Cells In Tumor Immunity to T
Page 85 and 86:
48 4 T Cells In Tumor Immunity Alth
Page 87 and 88:
50 4 T Cells In Tumor Immunity Tab.
Page 89 and 90:
52 4 T Cells In Tumor Immunity rest
Page 91 and 92:
54 4 T Cells In Tumor Immunity 53 T
Page 93 and 94:
Part 2 Immune Evasion and Suppressi
Page 95 and 96:
60 5 Major Histocompatibility Compl
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
68 Tab. 5.1 HLA class I loss attrib
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
96 6 Immune Cells in the Tumor Micr
Page 133 and 134:
98 6 Immune Cells in the Tumor Micr
Page 135 and 136:
100 6 Immune Cells in the Tumor Mic
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Tab. 7.1 Effects of tumor-derived m
Page 157 and 158:
122 7 Immunosuppresive Factors in C
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172: 136 7 Immunosuppresive Factors in C
Page 191 and 192: 156 8 Interleukin-10 in Cancer Immu
Page 211 and 212: Part 3 Strategies for Cancer Immuno
Page 213 and 214: 180 9 Dendritic Cells and Cancer: P
Page 221: 188 9 Dendritic Cells and Cancer: P
Page 237 and 238: 204 Cancer Immune Therapie: Current
Page 239 and 240: 206 10 The Immune System in Cancer:
Page 263 and 264: 230 Cancer Immune Therapie: Current
Page 265 and 266: 232 11 Hybrid Cell Vaccination for
Page 273 and 274:
240 11 Hybrid Cell Vaccination for
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
254 12 Principles and Strategies Em
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
270 13 Applications of CpG Motifs f
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
288 14 The T-Body Approach: Towards
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
300 15 Bone Marrow Transplantation
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
312 16 Immunocytokines: Versatile M
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
348 17 Immunotoxins and Recombinant
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
382 Glossary tion to the variable d
Page 417 and 418:
384 Glossary suppressor gene produc
Page 419 and 420:
386 Glossary press the proper recep
Page 421 and 422:
388 Glossary gp96 See Chaperone. Gr
Page 423 and 424:
390 Glossary cytes and addressing l
Page 425 and 426:
392 Glossary T bodies are being tes
show all

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Create successful ePaper yourself

Delete template?

Save as template?